The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy
Open accessAbstract
The Kirsten rat sarcoma (KRAS) oncoprotein has been on drug hunters list for decades now. Initially considered undruggable, recent advances have successfully broken the jinx through covalent inhibition that exploits the mutated cys12 in the switch II binding pocket (KRAS G12C). Though this approach has achieved some level of success, patients with mutations other than cys12 are still uncatered for. KRAS G12D is the most frequent KRAS mutated oncoprotein. It is only until recently, MRTX1133 has been discovered as a potential inhibitor of KRAS G12D. This study seeks to unravel the structural binding mechanism of MRTX1133 as well as identify potential drug leads of KRAS G12D based on structural binding characteristics of MRTX1133. It was revealed that MRTX1133 binding stabilizes the binding site by increasing the hydrophobicity which resultantly induced positive correlated movements of switches I and II which could disrupt their interaction with effector and regulatory proteins. Furthermore, MRTX1133 interacted with critical residues; Asp69 (− 4.54 kcal/mol), His95 (− 3.65 kcal/mol), Met72 (− 2.27 kcal/mol), Thr58 (− 2.23 kcal/mol), Gln99 (− 2.03 kcal/mol), Arg68 (− 1.67 kcal/mol), Tyr96 (− 1.59 kcal/mol), Tyr64 (− 1.34 kcal/mol), Gly60 (− 1.25 kcal/mol), Asp12 (− 1.04 kcal/mol), and Val9 (− 1.03 kcal/mol) that contributed significantly to the total free binding energy of − 73.23 kcal/mol. Pharmacophore-based virtual screening based on the structural binding mechanisms of MRTX1133 identified ZINC78453217, ZINC70875226 and ZINC64890902 as potential KRAS G12D inhibitors. Further, structural optimisations and biochemical testing of these compounds would assist in the discovery of effective KRAS G12D inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures












Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides, MRTX-1133 inhibited KRAS-dependent signaling and promoted tumor regression in xenograft models.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [255]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies demonstrated potent suppression of KRAS G12D signaling and marked antitumor activity in pancreatic and colorectal cancer models [51,53].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [53]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Daina, A., Michielin, O., & Zoete, V. (2017) · Scientific Reports · doi:10.1038/srep42717 · Cited by 18,367
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB
Maier, J. A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K. E., & Simmerling, C. (2015) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.5b00255 · Cited by 10,830
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data
Roe, D. R., & Cheatham, T. E. (2013) · Journal of Chemical Theory and Computation · doi:10.1021/ct400341p · Cited by 7,382
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
MMPBSA.py: An Efficient Program for End-State Free Energy Calculations
Miller, B. R., McGee, T. D., Swails, J. M., Homeyer, N., Gohlke, H., & Roitberg, A. E. (2012) · Journal of Chemical Theory and Computation · doi:10.1021/ct300418h · Cited by 4,609
Small-Molecule Library Screening by Docking with PyRx
Dallakyan, S., & Olson, A. J. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2269-7_19 · Cited by 3,998
Research works printed but not linked: 1
- Schweizer, L. & Mueller, L. protein conformational dynamics and signaling in evolution and pathophysiology. In Arey Pharmacology and Therapeutics 209–249 (Academic Press, San Diego, 2014).
Cited by
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Rudrapal, M., Eltayeb, W. A., Rakshit, G., El-Arabey, A. A., Khan, J., Aldosari, S. M., Alshehri, B., & Abdalla, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-35161-0 · Cited by 167
Self-citationIssahaku, A. R., Salifu, E. Y., Agoni, C., Alahmdi, M. I., Abo-Dya, N. E., Soliman, M. E. S., Rudrapal, M., & Naresh, P. (2023) · ChemistrySelect · doi:10.1002/slct.202300277 · Cited by 58
Self-citationÇapan, İ., Hawash, M., Qaoud, M. T., Gülüm, L., Tunoğlu, E. N. Y., Çifci, K. U., Çevrimli, B. S., Sert, Y., Servi, S., Koca, İ., et al. (2024) · BMC Chemistry · doi:10.1186/s13065-024-01207-1 · Cited by 54
“The preparation step encompassed various tasks, including assigning bond orders, adding hydrogen atoms, filling in missing side chains and loops using Prime, generating het states at pH 7 ± 1 using Epik, optimizing the protein structure, removing water molecules within a 3 Å range beyond hets, and…”
MethodVenkata, R. B., Prasanth, D., Pasala, P. K., Panda, S. P., Tatipamula, V. B., Mulukuri, N. V. L. S., Kota, R. K., Rudrapal, M., Khan, J., Aldosari, S., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1185236 · Cited by 52
Self-citation
Metadata
- Authors
- Issahaku, A. R., Mukelabai, N., Agoni, C., Rudrapal, M., Aldosari, S. M., Almalki, S. G., & Khan, J.
- Affiliations
- University of KwaZulu-Natal (ZA)
- Majmaah University (SA)
- Corresponding author
- Rudrapal, Mithun
- ORCID
- Venue
- Scientific Reports
- Published
- 2022-10-22
- Volume
- 12
- Issue
- 1
- Pages
- 17796-17796
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC9588042
- OpenAlex
- W4307138949
- Cited by
- 93
- References
- 66
- Citations by year
- 2026: 13 · 2025: 21 · 2024: 41 · 2023: 18
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- MRTX1133, KRAS G12D, KRAS inhibitors, covalent inhibition, binding free energy, hydrophobic stabilization, pharmacophore-based virtual screening, lead compound identification, cancer therapy
- MeSH terms
- Binding Sites, Humans, Mutation, Neoplasms, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy. https://app.cochat.ai/papers/10.1038/s41598-022-22668-1
- The paper
- Issahaku, A. R., Mukelabai, N., Agoni, C., Rudrapal, M., Aldosari, S. M., Almalki, S. G., & Khan, J. (2022). Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy. Scientific Reports. https://doi.org/10.1038/s41598-022-22668-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.